319 related articles for article (PubMed ID: 27148621)
1. Impact of levonorgestrel-releasing intrauterine system use on the cancer risk of the ovary and fallopian tube.
Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Pukkala E
Acta Oncol; 2016 Nov; 55(11):1281-1284. PubMed ID: 27148621
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel-releasing intrauterine system and the risk of breast cancer: A nationwide cohort study.
Soini T; Hurskainen R; Grénman S; Mäenpää J; Paavonen J; Joensuu H; Pukkala E
Acta Oncol; 2016; 55(2):188-92. PubMed ID: 26243443
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of the levonorgestrel-releasing intrauterine system in the treatment of heavy menstrual bleeding.
Cihangir U; Ebru A; Murat E; Levent Y
Int J Gynaecol Obstet; 2013 Nov; 123(2):146-9. PubMed ID: 24028852
[TBL] [Abstract][Full Text] [Related]
4. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
Jareid M; Thalabard JC; Aarflot M; Bøvelstad HM; Lund E; Braaten T
Gynecol Oncol; 2018 Apr; 149(1):127-132. PubMed ID: 29482839
[TBL] [Abstract][Full Text] [Related]
5. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on lower urinary tract symptoms: a 10-year follow-up study of a randomised trial.
Heliövaara-Peippo S; Halmesmäki K; Hurskainen R; Teperi J; Grenman S; Kivelä A; Tomas E; Tuppurainen M; Paavonen J
BJOG; 2010 Apr; 117(5):602-9. PubMed ID: 20156209
[TBL] [Abstract][Full Text] [Related]
6. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
[TBL] [Abstract][Full Text] [Related]
7. Levonorgestrel-releasing intrauterine system and breast cancer risk: A systematic review and meta-analysis.
Conz L; Mota BS; Bahamondes L; Teixeira Dória M; Françoise Mauricette Derchain S; Rieira R; Sarian LO
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):970-982. PubMed ID: 31990981
[TBL] [Abstract][Full Text] [Related]
8. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
Wildemeersch D; Janssens D; Andrade A
Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
[TBL] [Abstract][Full Text] [Related]
9. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system.
Bahamondes MV; Monteiro I; Castro S; Espejo-Arce X; Bahamondes L
Hum Reprod; 2010 May; 25(5):1158-64. PubMed ID: 20185512
[TBL] [Abstract][Full Text] [Related]
11. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
12. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Nelson AL
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
[TBL] [Abstract][Full Text] [Related]
13. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
14. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts.
Reid PC; Virtanen-Kari S
BJOG; 2005 Aug; 112(8):1121-5. PubMed ID: 16045528
[TBL] [Abstract][Full Text] [Related]
15. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years.
Nelson AL
Expert Opin Drug Deliv; 2017 Sep; 14(9):1131-1140. PubMed ID: 28696796
[TBL] [Abstract][Full Text] [Related]
16. Selection and performance of the levonorgestrel-releasing intrauterine system.
Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
[TBL] [Abstract][Full Text] [Related]
17. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
Römer T; Linsberger D
Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
[TBL] [Abstract][Full Text] [Related]
18. Two Years Follow-Up of Patients with Abnormal Uterine Bleeding after Insertion of the Levonorgestrel-Releasing Intrauterine System.
Cim N; Soysal S; Sayan S; Yildizhan B; Karaman E; Cetin O; Tolunay HE; Yildizhan R
Gynecol Obstet Invest; 2018; 83(6):569-575. PubMed ID: 29223999
[TBL] [Abstract][Full Text] [Related]
19. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil).
Pisoni CN; Cuadrado MJ; Khamashta MA; Hunt BJ
Lupus; 2006; 15(12):877-80. PubMed ID: 17211994
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel-releasing intrauterine system for heavy menstrual bleeding improves hemoglobin and ferritin levels.
Kaunitz AM; Bissonnette F; Monteiro I; Lukkari-Lax E; DeSanctis Y; Jensen J
Contraception; 2012 Nov; 86(5):452-7. PubMed ID: 22959906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
